Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-18
SponsorChina Medical University Hospital
About this trial
This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.
Eligibility criteria
Qualifiers
DSM-5 diagnosis of ADHD
Did not have any changes of ADHD treatment (pharmacological/psychological) within 4 weeks of entering the trial.
SNAP-IV inattention subscale >=12, or hyperactivity subscale >=12, or inattention+ hyperactivity subscales >=24
Disqualifiers
IQ<80
Allergic to omega-3
Physical disorders: thyroid function, cancer
Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder
Trial design
Treatments tested in this trial
- Omega-3
- Placebo
Treatment groups
100 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov